Nelson B Watts1, Jane A Cauley2, Rebecca D Jackson3, Andrea Z LaCroix4, Cora E Lewis5, JoAnn E Manson6, Joan M Neuner7, Lawrence S Phillips8,9, Marcia L Stefanick10, Jean Wactawski-Wende11, Carolyn Crandall12. 1. Mercy Health Osteoporosis and Bone Health Services, Cincinnati, Ohio 45236. 2. Graduate School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261. 3. Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, Ohio 43210. 4. Women's Health Center of Excellence, Family Medicine and Public Health, University of California, San Diego, La Jolla, California 92093. 5. Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294. 6. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115. 7. Medical College of Wisconsin Cancer Center Population Science, Division of General Internal Medicine and Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226. 8. Atlanta VA Medical Center, Decatur, Georgia 30033. 9. Division of Endocrinology and Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322. 10. Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305. 11. Department of Epidemiology and Environmental Health, University at Buffalo, State University of New York, Buffalo, New York 14214; and. 12. Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095.
Abstract
Context: The Women's Health Initiative (WHI) hormone therapy (HT) trials showed protection against hip and total fractures, but a later observational report suggested loss of benefit and a rebound increased risk after cessation of HT. Objective: The purpose of this study was to examine fractures after discontinuation of HT. Design and Setting: Two placebo-controlled randomized trials served as the study setting. Patients: Study patients included WHI participants (N = 15,187) who continued active HT or placebo through the intervention period and who did not take HT in the postintervention period. Interventions: Trial interventions included conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) in naturally menopausal women and CEE alone in women with prior hysterectomy. Main Outcome Measures: Total fractures and hip fractures through 5 years after discontinuation of HT were recorded. Results:Hip fractures were infrequent (∼2.5 per 1000 person-years); this finding was similar between trials and in former HT and placebo groups. There was no difference in total fractures in the CEE + MPA trial for former HT vs former placebo users (28.9 per 1000 person-years and 29.9 per 1000 person-years, respectively; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.87 to 1.09; P = 0.63); however, in the CEE-alone trial, total fractures were higher in former placebo users (36.9 per 1000 person-years) compared with the former active group (31.1 per 1000 person-years), a finding that was suggestive of a residual benefit of CEE against total fractures (HR, 0.85; 95% CI, 0.73 to 0.98; P = 0.03). Conclusions: We found no evidence for increased fracture risk, either sustained or transient, for former HT users compared with former placebo users after stopping HT. There was residual benefit for total fractures in former HT users from the CEE-alone study.
RCT Entities:
Context: The Women's Health Initiative (WHI) hormone therapy (HT) trials showed protection against hip and total fractures, but a later observational report suggested loss of benefit and a rebound increased risk after cessation of HT. Objective: The purpose of this study was to examine fractures after discontinuation of HT. Design and Setting: Two placebo-controlled randomized trials served as the study setting. Patients: Study patients included WHI participants (N = 15,187) who continued active HT or placebo through the intervention period and who did not take HT in the postintervention period. Interventions: Trial interventions included conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) in naturally menopausal women and CEE alone in women with prior hysterectomy. Main Outcome Measures: Total fractures and hip fractures through 5 years after discontinuation of HT were recorded. Results:Hip fractures were infrequent (∼2.5 per 1000 person-years); this finding was similar between trials and in former HT and placebo groups. There was no difference in total fractures in the CEE + MPA trial for former HT vs former placebo users (28.9 per 1000 person-years and 29.9 per 1000 person-years, respectively; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.87 to 1.09; P = 0.63); however, in the CEE-alone trial, total fractures were higher in former placebo users (36.9 per 1000 person-years) compared with the former active group (31.1 per 1000 person-years), a finding that was suggestive of a residual benefit of CEE against total fractures (HR, 0.85; 95% CI, 0.73 to 0.98; P = 0.03). Conclusions: We found no evidence for increased fracture risk, either sustained or transient, for former HT users compared with former placebo users after stopping HT. There was residual benefit for total fractures in former HT users from the CEE-alone study.
Authors: Rebecca D Jackson; Jean Wactawski-Wende; Andrea Z LaCroix; Mary Pettinger; Robert A Yood; Nelson B Watts; John A Robbins; Cora E Lewis; Shirley Aa Beresford; Marcia G Ko; Michelle J Naughton; Suzanne Satterfield; Tamsen Bassford Journal: J Bone Miner Res Date: 2006-06 Impact factor: 6.741
Authors: Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin Journal: Bone Date: 2008-04-26 Impact factor: 4.398
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Richard D Wasnich; Yu Z Bagger; David J Hosking; Michael R McClung; Mei Wu; Ann Marie Mantz; John J Yates; Philip D Ross; Peter Alexandersen; Pernille Ravn; Claus Christiansen; Arthur C Santora Journal: Menopause Date: 2004 Nov-Dec Impact factor: 2.953
Authors: Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres Journal: Endocrine Date: 2019-04-08 Impact factor: 3.633
Authors: Gina N Woods; Mei-Hua Huang; Peggy M Cawthon; Corinne McDaniels-Davidson; Howard A Fink; Deborah M Kado Journal: Menopause Date: 2018-07 Impact factor: 2.953
Authors: S Rozenberg; N Al-Daghri; M Aubertin-Leheudre; M-L Brandi; A Cano; P Collins; C Cooper; A R Genazzani; T Hillard; J A Kanis; J-M Kaufman; I Lambrinoudaki; A Laslop; E McCloskey; S Palacios; D Prieto-Alhambra; J-Y Reginster; R Rizzoli; G Rosano; F Trémollieres; N C Harvey Journal: Osteoporos Int Date: 2020-07-08 Impact factor: 4.507